TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
18 mars 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 18, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
11 mars 2019 06h27 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Sen-Jam Pharmaceutical Underscores the Urgent Need to Revolutionize Pain Management and End the Opioid Epidemic at the 2019 StartUp Health Festival
13 févr. 2019 08h00 HE
|
Sen-Jam Pharmaceutical
HUNTINGTON, N.Y., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Sen-Jam Pharmaceutical, a therapeutic company focused on bringing relief to the opioid crisis, was delighted to present at the 2019 StartUp Health...
TLC Announces Phase I/II Full Enrollment in Hernia Repair Surgery and Phase II Initiation in Bunionectomy of TLC590 for Postsurgical Pain
18 déc. 2018 05h30 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients
12 déc. 2018 07h30 HE
|
Pacira Pharmaceuticals, Inc.
Results show incorporating transversus abdominis plane block with EXPAREL results in significantly improved patient functional recovery and hospital throughput Twelve percent of patients receiving...
SPR Therapeutics Awarded $10M From U.S. Department of Defense
02 oct. 2018 10h30 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, has been awarded two new grants and one new contract from the U.S....
TLC Doses First Patients in Phase I/II Trial of TLC590 for Postsurgical Pain Management
14 août 2018 04h55 HE
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the...
Global Market for Non-opioid Pain Treatment to Easily Double in 5 Years
21 févr. 2018 14h30 HE
|
BCC Research
WELLESLEY, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- As pain treatment becomes more multidisciplinary and the use of alternative non-opioid treatments expands, along with the growing acceptance of...